Clinical Trial Detail

NCT ID NCT03138889
Title A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Nektar Therapeutics
Indications

non-small cell lung carcinoma

Therapies

NKTR-214 + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST